a Internal Medicine Department , AP-HP, Ambroise-Paré Hospital , Boulogne-Billancourt , France.
b Ophthalmology Department , AP-HP, Groupe Hospitalier Pitié-Salpêtrière , Paris , France.
Ocul Immunol Inflamm. 2018;26(8):1192-1199. doi: 10.1080/09273948.2017.1332232. Epub 2017 Jul 12.
To clarify interferon-gamma release assay (IGRA) contributions to intraocular tuberculosis management, according to related TB endemic prevalence.
Despite extensive investigations, including IGRA, the diagnosis of intraocular tuberculosis (TB) is still challenging and remains mostly presumptive. According to the literature, it appears that management of suspected ocular TB differs significantly based on whether patients are from areas of high TB prevalence or from non-TB-endemic countries. The accuracy and final contribution of chest X-rays, tuberculin skin test and IGRA differ significantly according to low or high endemic TB areas. This work aims to review IGRA test outcomes in the light of these clinical and epidemiological settings. We therefore focused our analysis and its subsequent guidelines proposal based on the TB prevalence where the patient lives.
We believe that distinct guidelines should be determined for managing patients with suspected ocular TB, first taking into consideration the relative TB prevalence.
根据相关结核病流行率，明确干扰素 -γ释放试验（IGRA）在眼内结核管理中的作用。
尽管进行了广泛的调查，包括 IGRA，但眼内结核（TB）的诊断仍然具有挑战性，并且仍然主要是推测性的。根据文献，疑似眼 TB 的治疗似乎因患者来自高 TB 流行地区还是非 TB 流行国家而有很大差异。根据低流行或高流行 TB 地区，胸部 X 光、结核菌素皮肤试验和 IGRA 的准确性和最终贡献有很大差异。这项工作旨在根据这些临床和流行病学情况，审查 IGRA 检测结果。因此，我们根据患者所在地区的结核病流行率，对分析及其后续指南建议进行了重点关注。
我们认为，应该根据相对 TB 流行率，为疑似眼 TB 患者的管理制定不同的指南。
